Exocrine pancreatic carcinoma
MONDO:0005192A carcinoma that arises from epithelial cells of the exocrine pancreas
Also known as: cancer of pancreas, cancer of the pancreas, exocrine cancer, pancreas cancer, pancreatic cancer, carcinoma of exocrine pancreas, carcinoma of the pancreas, exocrine pancreas carcinoma
3851 clinical trials for this condition and its sub-types, 205 tagged with Exocrine pancreatic carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Exocrine pancreatic carcinoma
-
Pancreatic adenocarcinoma 497 trials · 930 incl. sub-types
5 sub-types
- Pancreatic ductal adenocarcinoma 553 trials Sub-types →
- Pancreatic acinar cell carcinoma 12 trials Sub-types →
- Pancreatic intraductal papillary-mucinous neoplasm with an associated invasive carcinoma 1 trial
- Mucinous pancreas adenocarcinoma 0 trials
- Pancreatic cystadenocarcinoma 0 trials Sub-types →
-
Squamous cell carcinoma of pancreas 3 trials · 13 incl. sub-types
1 sub-type
- Pancreatic adenosquamous carcinoma 13 trials
-
Familial pancreatic carcinoma 9 trials
-
Pancreatic intraductal papillary-mucinous carcinoma 0 trials · 2 incl. sub-types
-
Pancreatic mucinous cystadenoma 1 trial
Most studied deeper sub-types
-
Personalized drug matching put to the test in pancreatic cancer
Disease control Not yet recruitingThis phase 2 trial tests whether choosing treatment based on the genetic changes in a person's pancreatic cancer works better than standard chemotherapy. Adults with advanced pancreatic cancer that has progressed after first-line treatment may join if their tumor has a genetic ch…
Phase 2 • Sponsor: Herlev Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug targets Hard-to-Treat pancreatic cancer by hitting a common mutation
Disease control Not yet recruitingThis trial tests a new drug called DN022150 in people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. Participants have already received at least one prior treatment. The study compares DN022150 alone against standard chemotherapy options to s…
Phase 3 • Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug combo targets tough pancreatic cancer gene
Disease control Not yet recruitingThis study tests a new drug called DN022150 combined with standard chemotherapy (AG) as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. About 465 adults aged 18-75 who have not had prior treatment for advanced disease will tak…
Phase 2/3 • Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug targets tough cancers with KRas G12V mutation
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called CLSP-5282 in up to 140 adults with advanced solid tumors (like lung, pancreatic, or colorectal cancer) that have a specific genetic change called KRas G12V. The drug is given by IV infusion. The main goals are to check safe…
Phase 1 • Sponsor: Clasp Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New personalized vaccine takes on tough cancers
Disease control Not yet recruitingThis early-stage trial tests a personalized cancer vaccine called ODI-2001 in 77 people with advanced colon or pancreatic cancer that has spread or cannot be removed. The vaccine is custom-made for each patient's tumor and is given along with a drug that boosts the immune system.…
Phase 1 • Sponsor: Centre Georges Francois Leclerc • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for pancreatic cancer: combo therapy enters phase 2 trial
Disease control Not yet recruitingThis study tests a new treatment for people with advanced pancreatic cancer that has not been treated before. It combines a hedgehog inhibitor (NLM-001) with standard chemotherapy and two immunotherapy drugs. The goal is to see if this combination shrinks tumors better than chemo…
Phase 2 • Sponsor: Nelum Corp • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for pancreatic cancer: experimental drug MRG004A enters final testing phase
Disease control Not yet recruitingThis phase 3 trial tests whether the experimental drug MRG004A, combined with best supportive care, helps people with advanced pancreatic cancer live longer compared to a placebo. The study plans to enroll 231 adults whose cancer has not responded to standard treatments. Particip…
Phase 3 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New surgical order may boost pancreatic cancer outcomes
Disease control Not yet recruitingThis study tests whether changing the order of steps during a Whipple surgery for pancreatic head cancer can help surgeons remove the tumor more completely and lower the chance of cancer coming back. About 150 adults with operable pancreatic cancer will be randomly assigned to ei…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for tough pancreatic cancer? experimental combo enters human testing
Disease control Not yet recruitingThis phase 2 trial tests an experimental oral liquid called BLEX 404 combined with standard chemotherapy (gemcitabine) in 40 people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The study first finds a safe dose, then checks if the combo shrinks…
Phase 2 • Sponsor: Rgene Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug cocktail targets Hard-to-Treat gut cancers
Disease control Not yet recruitingThis Phase 2 trial tests a combination of tunlametinib and anti-EGFR antibodies (cetuximab β or nimotuzumab) in 90 adults with advanced colorectal or pancreatic cancers that have RAS mutations and have not responded to standard treatments. The goal is to see if the combo shrinks …
Phase 2 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New cell therapy aims to train immune system against hard-to-treat cancers
Disease control Not yet recruitingThis early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Triple threat: radiation and immunotherapy join chemo against pancreatic cancer
Disease control Not yet recruitingThis Phase III trial tests whether adding targeted radiation and an immunotherapy drug (serplulimab) to standard chemotherapy can help people with advanced pancreatic cancer live longer. About 198 participants who have not had prior treatment will be randomly assigned to receive …
Phase 3 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New cocktail of drugs aims to tackle tough pancreatic cancer
Disease control Not yet recruitingThis study tests a combination of four drugs—tunlametinib, two chemotherapies, and a targeted antibody—as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The trial will enroll 28 patients who have not had prior therapy. Researchers …
Phase 4 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Can a radiation boost help fight pancreatic cancer?
Disease control Not yet recruitingThis study looks at whether giving a higher dose of radiation (60-65 Gy) using a precise technique called VMAT can help people with inoperable pancreatic cancer live longer and keep their tumors under control compared to the standard lower dose (45-50.4 Gy). Researchers will foll…
Sponsor: Chifeng Tumor Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Experimental vaccine takes on tough pancreatic cancer
Disease control Not yet recruitingThis early-phase trial will test a new tumor vaccine (SapDM275) combined with standard chemotherapy in 13 people with metastatic pancreatic cancer who have not had prior treatment. The vaccine aims to help the immune system attack cancer cells. The main goal is to check safety, b…
Early phase 1 • Sponsor: The Third Xiangya Hospital of Central South University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a phone app help pancreatic cancer patients eat better during treatment?
Symptom relief Not yet recruitingResearchers are testing whether a digital nutrition app called STRONG, paired with remote dietitian counseling, is practical and helpful for adults with pancreatic ductal adenocarcinoma who are starting chemotherapy or radiation. About 80 participants join the study and are assig…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a spinal pump deliver better pain relief for pancreatic cancer?
Symptom relief Not yet recruitingThis pilot study tests whether delivering pain medication directly to the spinal cord via an implanted pump can better control severe pain in people with pancreatic cancer. The trial enrolls adults whose pain is not well managed by standard treatments or who cannot take typical p…
Sponsor: Clinique Bizet • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Lifting weights against cancer: new study tests Muscle-Saving exercise for pancreatic patients
Symptom relief Not yet recruitingThis study tests whether a 12-week supervised strength training program can help people with advanced pancreatic cancer maintain muscle mass and improve their quality of life. Ten participants who are receiving chemotherapy or immunotherapy will be randomly assigned to either the…
Sponsor: Universidad Europea de Madrid • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Tube Tug-of-War: keeping or removing drain during pancreatic surgery may cut complications
Knowledge-focused Not yet recruitingThis trial looks at whether keeping or removing a drainage tube (PTCD catheter) during pancreatic surgery leads to fewer complications. About 100 patients with jaundice from tumors will be randomly assigned to one of two groups. The main goal is to see which approach reduces seri…
Sponsor: Xu'an Wang • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
MRI vs. CT: new study aims to sharpen cancer radiotherapy
Knowledge-focused Not yet recruitingThis study tests whether using MRI scans to plan radiotherapy is better than using CT scans alone. Researchers will work with up to 150 cancer patients and 15 healthy volunteers to see if MRI can make treatment more precise and reduce side effects. The goal is to improve how tumo…
Sponsor: Swansea Bay University Health Board • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
Study to track pain and expectations in 200 cancer surgery patients
Knowledge-focused Not yet recruitingThis study will follow 200 adults undergoing surgery for liver, esophagus, or pancreatic cancer. Researchers want to see how patients' expectations before surgery relate to their pain, painkiller use, and recovery afterward. The goal is to learn how to better manage pain and impr…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:28 UTC